Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Palisade Bio (7NS0) Stock Price & Analysis

7NS0 Stock Chart & Stats

€5.01€0.00(0.00%)
At close: 5:30 PM GMT+1
EUR 7.5EUR 10EUR 12.54 Dec28 Dec29 Jan6 Feb
Day’s Range
EUR 5.01 - EUR 5.36
52-Week Range
EUR 5.01 - EUR 5.36
Previous Close
EUR 5.01
Volume
0
Average Volume (3M)
0
Market Cap
EUR 180.40M
Enterprise Value
EUR 316.62M
Total Cash (Recent Filing)
EUR 125.17M
Total Debt (Recent Filing)
EUR 0
Price to Earnings (P/E)
―
Beta
N/A
Next Earnings
Nov 16, 2026 (Est.)
EPS Estimate
-0.05
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Low Leverage

Minimal debt reduces mandatory financing costs and repayment pressure while preserving flexibility to direct capital toward research and development. For a clinical-stage biotech without product revenue, this conservative capital structure provides greater resilience as programs advance through development.

Substantial Equity Base

A sizable equity base gives Palisade Bio financial capacity to support ongoing development activities and absorb operating losses more effectively than a highly leveraged structure. This capital cushion can help preserve strategic flexibility while the company seeks to advance its pipeline.

Focused GI Therapeutics Pipeline

Concentrating research on gastrointestinal diseases creates a coherent development strategy and allows the company to build expertise around a defined therapeutic area. The stated potential for development or commercialization partnerships could also support future pipeline advancement.

Bears Say

Pre-Revenue Business Model

The absence of recurring product revenue means Palisade Bio currently depends on capital resources and successful development outcomes rather than commercial operations. This limits internal funding capacity and leaves the business model exposed to delays in reaching potential commercialization.

Widening Net Losses

The sharp increase in losses indicates that operating spending is expanding faster than the company’s ability to generate revenue. Persistently negative earnings can consume the equity base over time and increase the financing required to maintain development programs.

Increasing Cash Burn

Higher cash consumption raises the amount of capital required to sustain research and clinical activities before any commercial cash inflows emerge. If the elevated burn rate persists, funding needs may increase and could constrain the pace or scope of pipeline development.

Palisade Bio News

7NS0 FAQ

What was Palisade Bio’s price range in the past 12 months?
Palisade Bio lowest stock price was €5.01 and its highest was €5.36 in the past 12 months.
What is Palisade Bio’s market cap?
Palisade Bio’s market cap is €180.40M.
When is Palisade Bio’s upcoming earnings report date?
Palisade Bio’s next earnings report is estimated for Nov 16, 2026 (not yet confirmed), which is in 14 days.
How were Palisade Bio’s earnings last quarter?
Palisade Bio released its earnings results on Aug 10, 2026. The company reported -€0.045 earnings per share for the quarter, beating the consensus estimate of -€0.046 by €0.002.
Is Palisade Bio overvalued?
According to Wall Street analysts Palisade Bio’s price is currently Undervalued.
Does Palisade Bio pay dividends?
Palisade Bio does not currently pay dividends.
What is Palisade Bio’s EPS estimate?
Palisade Bio’s EPS estimate is -0.05.
How many shares outstanding does Palisade Bio have?
Palisade Bio has 174,270,550 shares outstanding.
What happened to Palisade Bio’s price movement after its last earnings report?
Palisade Bio reported an EPS of -€0.045 in its last earnings report, beating expectations of -€0.046. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Palisade Bio?
Hedge funds hold Palisade Bio shares: the largest hedge-fund position in Palisade Bio is 1,800,360,037 shares, and hedge funds decreased their holdings by 110.5K shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology